INFORMATION FOR
News
Publications regarding cancer attributed to first- and last-authors of published papers
Joseph Brito, III, MD, participates in a Q&A in honor of Bladder Cancer Awareness Month.
Learn about Yale Urology's new tradition and how it serves as seed money, encouraging faculty to take calculated risks and try new approaches that may lead to innovative patient care solutions.
On April 2, 2024, members of the Prostate and Urologic Cancers Program at Smilow Cancer Hospital discussed the management of bladder cancer.
Dr. Fed Ghali on Yale Cancer Answers.
To me, being a survivor means I was lucky enough to be diagnosed with cancer in this day and age.
The U.S. Food and Drug Administration has granted accelerated approval to the drug enfortumab vedotin to treat adult patients with advanced urothelial or bladder cancer. The approval is the direct result of a multi-institutional clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers.
Dr. Daniel Petrylak talks about his new research presented at the 2017 European Society for Medical Oncology (ESMO) conference showing promising treatment for patients battling advanced Bladder cancer.
A new immunotherapy, tested in phase I and II trials at Smilow Cancer Hospital and other top cancer centers, has shown tremendous promise in the treatment of bladder cancer.